The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease


Falcone C., Geroldi D., Buzzia M. P., Ernanuele E., YILMAZ Y., Fontana J. M., ...More

ARCHIVES OF MEDICAL RESEARCH, vol.39, no.3, pp.320-325, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 3
  • Publication Date: 2008
  • Doi Number: 10.1016/j.arcmed.2007.11.003
  • Journal Name: ARCHIVES OF MEDICAL RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.320-325
  • Bursa Uludag University Affiliated: No

Abstract

Background. The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis. No data are currently available on the potential prognostic role of this polymorphism in patients with angiographically proven coronary artery disease (CAD). Hereto we sought to address this issue in a large consecutive cohort of patients undergoing coronary revascularization.